Manisha Bhutani

Manisha Bhutani

Hematology | Oncology

1021 Morehead Medical Drive
Building 2, Suite 60201
Charlotte, NC 28204

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 78 publications

Access to T-Cell Redirecting Therapies in Multiple Myeloma: Patient, Caregiver, and Physician Perspectives on Awareness and Barriers.

Access to T-Cell Redirecting Therapies in Multiple Myeloma: Patient, Caregiver, and Physician Perspectives on Awareness and Barriers.

Journal: Cancers

Published: June 26, 2026

Teclistamab and Daratumumab Immune-Based Doublet Therapy for Relapsed/Refractory Multiple Myeloma: the TRIMM-2 Study.

Teclistamab and Daratumumab Immune-Based Doublet Therapy for Relapsed/Refractory Multiple Myeloma: the TRIMM-2 Study.

Journal: Blood advances

Published: April 03, 2026

Performance evaluation of an automated mass spectrometry system for the measurement and isotyping of monoclonal immunoglobulins.

Performance evaluation of an automated mass spectrometry system for the measurement and isotyping of monoclonal immunoglobulins.

Journal: Clinica chimica acta; international journal of clinical chemistry

Published: December 11, 2025

Belantamab mafodotin, carfilzomib, lenalidomide, and dexamethasone for relapsed or refractory multiple myeloma.

Belantamab mafodotin, carfilzomib, lenalidomide, and dexamethasone for relapsed or refractory multiple myeloma.

Journal: Blood advances

Published: November 10, 2025

Belantamab mafodotin, carfilzomib, lenalidomide, and dexamethasone for relapsed or refractory multiple myeloma.

Belantamab mafodotin, carfilzomib, lenalidomide, and dexamethasone for relapsed or refractory multiple myeloma.

Journal: Blood advances

Published: November 10, 2025

Daratumumab-Bortezomib-Cyclophosphamide-Dexamethasone in Newly Diagnosed Amyloidosis: ANDROMEDA Final Survival Analysis.

Daratumumab-Bortezomib-Cyclophosphamide-Dexamethasone in Newly Diagnosed Amyloidosis: ANDROMEDA Final Survival Analysis.

Journal: Blood

Published: October 20, 2025

Daratumumab-bortezomib-cyclophosphamide-dexamethasone for newly diagnosed amyloidosis: ANDROMEDA final survival analysis.

Daratumumab-bortezomib-cyclophosphamide-dexamethasone for newly diagnosed amyloidosis: ANDROMEDA final survival analysis.

Journal: Blood

Published: October 20, 2025

Comparative Efficacy of Talquetamab vs. Real-World Physician's Choice of Treatment in Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma: Updated Analyses of MonumenTAL-1 vs. LocoMMotion/MoMMent.

Comparative Efficacy of Talquetamab vs. Real-World Physician's Choice of Treatment in Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma: Updated Analyses of MonumenTAL-1 vs. LocoMMotion/MoMMent.

Journal: Advances in therapy

Published: September 02, 2025

Outcomes of CAR T-Cell therapy in relapsed/refractory multiple myeloma by race: a multicenter real-world study.

Outcomes of CAR T-Cell therapy in relapsed/refractory multiple myeloma by race: a multicenter real-world study.

Journal: Blood cancer journal

Published: July 24, 2025

Resistance Mechanisms to BCMA Targeting Bispecific Antibodies and CAR T-Cell Therapies in Multiple Myeloma.

Resistance Mechanisms to BCMA Targeting Bispecific Antibodies and CAR T-Cell Therapies in Multiple Myeloma.

Journal: Cells

Published: June 02, 2025

Sequential targeting in multiple myeloma: talquetamab, a GPRC5D bispecific antibody, as a bridge to BCMA CAR-T therapy.

Sequential targeting in multiple myeloma: talquetamab, a GPRC5D bispecific antibody, as a bridge to BCMA CAR-T therapy.

Journal: Blood

Published: May 05, 2025

Plasma Proteomic Profiles Among White and African American Individuals With Monoclonal Gammopathy of Unknown Significance (MGUS) and Multiple Myeloma (MM).

Plasma Proteomic Profiles Among White and African American Individuals With Monoclonal Gammopathy of Unknown Significance (MGUS) and Multiple Myeloma (MM).

Journal: Clinical lymphoma, myeloma & leukemia

Published: April 22, 2025

Showing 1-12 of 78

Last Updated: 09/26/2026